IN2014DN10390A - - Google Patents

Download PDF

Info

Publication number
IN2014DN10390A
IN2014DN10390A IN10390DEN2014A IN2014DN10390A IN 2014DN10390 A IN2014DN10390 A IN 2014DN10390A IN 10390DEN2014 A IN10390DEN2014 A IN 10390DEN2014A IN 2014DN10390 A IN2014DN10390 A IN 2014DN10390A
Authority
IN
India
Prior art keywords
human patient
nucleotides
treating
lung cancer
small cell
Prior art date
Application number
Other languages
English (en)
Inventor
Chen Duksin
Shoshi Tessler
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IN2014DN10390A publication Critical patent/IN2014DN10390A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN10390DEN2014 2012-05-18 2013-05-17 IN2014DN10390A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261649092P 2012-05-18 2012-05-18
PCT/US2013/041652 WO2013173757A1 (en) 2012-05-18 2013-05-17 Method for treating non-small cell lung cancer

Publications (1)

Publication Number Publication Date
IN2014DN10390A true IN2014DN10390A (zh) 2015-08-14

Family

ID=49581824

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10390DEN2014 IN2014DN10390A (zh) 2012-05-18 2013-05-17

Country Status (17)

Country Link
US (1) US20130310440A1 (zh)
EP (1) EP2849761A1 (zh)
JP (1) JP2015522542A (zh)
KR (1) KR20150024843A (zh)
CN (1) CN104684564A (zh)
AR (1) AR091090A1 (zh)
AU (1) AU2013262589A1 (zh)
BR (1) BR112014028787A2 (zh)
CA (1) CA2874092A1 (zh)
EA (1) EA201492148A1 (zh)
IL (1) IL235459A0 (zh)
IN (1) IN2014DN10390A (zh)
PH (1) PH12014502569A1 (zh)
SG (1) SG11201407649RA (zh)
TW (1) TW201402132A (zh)
UY (1) UY34812A (zh)
WO (1) WO2013173757A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1163254B1 (en) 1999-02-26 2008-01-30 The University of British Columbia Trpm-2 antisense therapy
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
LT3581105T (lt) 2010-05-08 2022-12-27 The Regents Of The University Of California Opų ankstyvojo aptikimo skenuojant subepiderminį drėgnį aparatas
SG192957A1 (en) 2011-03-15 2013-09-30 Univ British Columbia Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer
CN104473973B (zh) * 2014-12-19 2015-08-05 山东创新药物研发有限公司 一株戈氏梭菌驯化株的应用
CA3059988C (en) 2015-04-24 2023-03-07 Bruin Biometrics, Llc Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements
US11337651B2 (en) 2017-02-03 2022-05-24 Bruin Biometrics, Llc Measurement of edema
KR102492905B1 (ko) 2017-02-03 2023-01-31 브루인 바이오메트릭스, 엘엘씨 조직 생존률의 측정
CN109890282A (zh) 2017-02-03 2019-06-14 布鲁恩生物有限责任公司 糖尿病足溃疡易感性的测量
EP3562390A4 (en) 2017-11-16 2020-12-09 Bruin Biometrics, LLC PROVISION OF CONTINUITY OF CARE IN MULTIPLE CARE FACILITIES
WO2019136287A1 (en) * 2018-01-05 2019-07-11 LifeUnit Inc. Adjuvant chemicals that prevent drug tolerance and persister formation by bacteria
SI3749181T1 (sl) 2018-02-09 2024-06-28 Bruin Biometrics, LLC, Odkrivanje poškodb na tkivu
SG11202103318VA (en) 2018-10-11 2021-04-29 Bruin Biometrics Llc Device with disposable element
MX2023009108A (es) 2021-02-03 2023-08-09 Bruin Biometrics Llc Métodos de tratamiento de daño tisular inducido por presión en estadio profundo y temprano.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US8710020B2 (en) * 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
EP2300825A4 (en) * 2008-06-18 2012-04-25 Abbott Lab P / GF 1 COMPARATIVE DIAGNOSTIC PROCEDURES AND PRODUCTS
WO2012156817A2 (en) * 2011-05-19 2012-11-22 Teva Pharmaceutical Industries Ltd. Method for treating non-small cell lung cancer

Also Published As

Publication number Publication date
BR112014028787A2 (pt) 2017-06-27
AR091090A1 (es) 2014-12-30
EA201492148A1 (ru) 2015-04-30
UY34812A (es) 2013-12-31
CA2874092A1 (en) 2013-11-21
KR20150024843A (ko) 2015-03-09
WO2013173757A1 (en) 2013-11-21
JP2015522542A (ja) 2015-08-06
PH12014502569A1 (en) 2015-01-21
AU2013262589A1 (en) 2015-01-22
CN104684564A (zh) 2015-06-03
WO2013173757A8 (en) 2015-04-30
IL235459A0 (en) 2014-12-31
SG11201407649RA (en) 2014-12-30
EP2849761A1 (en) 2015-03-25
US20130310440A1 (en) 2013-11-21
TW201402132A (zh) 2014-01-16

Similar Documents

Publication Publication Date Title
IN2014DN10390A (zh)
MX2013013384A (es) Metodo para tratamiento de cancer de pulmon de celulas no pequeñas.
NZ603901A (en) Vectors and sequences for the treatment of diseases
NZ715081A (en) Antisense oligomers and conjugates targeting pcsk9
MX2015011943A (es) Acidos ribonucleicos con nucleotidos modificados por 4'-tio y metodos relacionados.
NZ762477A (en) Raav-based compositions and methods for treating amyotrophic lateral sclerosis
PH12015501953A1 (en) Substituted nucleotide analogs
EP3698631A3 (en) Methods of delivering oligonucleotides to immune cells
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
MX359548B (es) Agentes de iarn modificados.
EA201490563A1 (ru) Антисмысловые олигонуклеотиды для лечения врожденного амавроза лебера
WO2014191359A9 (en) Aptamers and use of the aptamers in the diagnosis and treatment of cancer
WO2011163499A3 (en) Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
NZ630914A (en) Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
BR112015009559A2 (pt) uso de composto antissenso na preparação de medicamento para tratamento de cãncer, composto antissenso e composição farmacêutica
WO2011121453A3 (en) Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
WO2011103528A3 (en) Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
MX2013005875A (es) Inhibidores de microarn que comprenden nucleotidos bloqueados.
WO2011005566A3 (en) Aptamer-targeted sirna to inhibit nonsense mediated decay
TN2015000079A1 (en) Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
MX2017014641A (es) Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa).
MX2024000277A (es) Microarns modificados con 5-halouracilo y su uso en el tratamiento del cancer.
BR112013002738A2 (pt) métodos e compostos para o diagnóstico e o tratamento do câncer
WO2015032800A3 (en) Compositions and methods for inducing senescence in cancer cells
WO2012145597A3 (en) Recombinant virus products and methods for inhibition of expression of myotilin